Behavioral recovery following sub-chronic paeoniflorin administration in the striatal 6-OHDA lesion rodent model of Parkinson's disease

被引:61
作者
Liu, Da-Zhi
Zhu, Jun
Jin, Dao-Zhong
Zhang, Li-Min
Ji, Xin-Quan
Ye, Yang
Tang, Chun-Ping
Zhu, Xing-Zu
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Dept Pharmacol 2, Shanghai 201203, Peoples R China
[2] Fudan Univ, Shanghai Med Coll, Dept Neurol, Huashan Hosp, Shanghai 200040, Peoples R China
[3] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
关键词
paeoniflorin; Paeoniae radix; behavior recovery adenosine A(1) receptor; striatal 6-hydroxydopamine-lesion rat; non-dopaminergic approach; Parkinson's disease;
D O I
10.1016/j.jep.2007.03.022
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
In the present studies, the effect of paeoniflorin (PF), one of the main compounds extracted from Paeoniae radix, in alleviating the neurological impairment following unilateral striatal 6-hydroxydopamine (6-OHDA) lesion was examined in Sprague-Dawley rats. Sub-chronic PF (2.5, 5 and 10mg/kg, s.c., twice daily for 11 days) administration dose-dependently reduced apornorphine (APO)-induced rotation, suggesting that PF had an ameliorative effect on the 6-OHDA-induced neurological impairment. Notably, PF had no direct action on dopamine D-1 receptor or dopamine D-2 receptor indicated by the competitive binding experiments. These results suggest that PF, an active component of Paeoniae radix, might provide an opportunity to introduce a non-dopaminergic management of Parkinson's disease. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:327 / 332
页数:6
相关论文
共 35 条
[1]   Protective effects of N-acetylserotonin against 6-hydroxydopamine-induced neurotoxicity [J].
Aguiar, LM ;
Macedo, DS ;
de Freitas, RM ;
Oliveira, AD ;
Vasconcelos, SMM ;
de Sousa, FCF ;
Viana, GSD .
LIFE SCIENCES, 2005, 76 (19) :2193-2202
[2]  
[Anonymous], EXP REV NEUROTHERAPE
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   Paeoniflorin reverses guanethidine-induced hypotension via activation of central adenosine A1 receptors in Wistar rats [J].
Cheng, JT ;
Wang, CJ ;
Hsu, FL .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1999, 26 (10) :815-816
[5]   Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease [J].
Clarke, CE .
LANCET NEUROLOGY, 2004, 3 (08) :466-474
[6]  
COLLIS MG, 1993, TRENDS PHARMACOL SCI, V14, P360
[7]   PHYSIOLOGICAL AND PHARMACOLOGICAL PROPERTIES OF ADENOSINE - THERAPEUTIC IMPLICATIONS [J].
DAVAL, JL ;
NEHLIG, A ;
NICOLAS, F .
LIFE SCIENCES, 1991, 49 (20) :1435-1453
[8]  
DELLEDONNE KT, 1994, J PHARMACOL EXP THER, V271, P1320
[9]   The role and regulation of adenosine in the central nervous system [J].
Dunwiddie, TV ;
Masino, SA .
ANNUAL REVIEW OF NEUROSCIENCE, 2001, 24 :31-55
[10]   Stimulation of adenosine A1 receptors attenuates dopamine D1 receptor-mediated increase of NGFI-A, c-fos and jun-B mRNA levels in the dopamine-denervated striatum and dopamine D1 receptor-mediated turning behaviour [J].
Ferré, S ;
Rimondini, R ;
Popoli, P ;
Reggio, R ;
Pèzzola, A ;
Hansson, AC ;
Andersson, A ;
Fuxe, K .
EUROPEAN JOURNAL OF NEUROSCIENCE, 1999, 11 (11) :3884-3892